Clinical and virological features of SARS-CoV-2 Omicron variant-infected immunocompromised patients receiving immunosuppressive medications.
COVID-19
Immunocompromised patients
Immunosuppressive medications
SARS-CoV-2
Severity
Viremia
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
25 Jul 2024
25 Jul 2024
Historique:
received:
10
04
2024
accepted:
18
07
2024
medline:
27
7
2024
pubmed:
27
7
2024
entrez:
26
7
2024
Statut:
epublish
Résumé
The prognosis of immunocompromised individuals with COVID-19 remains a significant concern. Information regarding the clinical and virological characteristics of immunocompromised patients infected with SARS-CoV-2 during the Omicron variant period is limited. Medical records of patients admitted to our hospital with COVID-19 during the Omicron (BA.1-5) epidemic were retrospectively reviewed. Clinical, virological (nasopharyngeal swabs and blood), and serological data were compared between immunocompromised patients receiving immunosuppressive medications (calcineurin inhibitors, mycophenolate mofetil, or steroids) and control patients not receiving immunosuppressive medications. Twenty-eight immunocompromised patients (25 transplant recipients) and 26 control patients were included. Fourteen of the immunocompromised patients (50%) received monoclonal antibodies. The immunocompromised group included 15 mild/moderate (53.6%), 10 severe (35.7%), and three critical (10.7%) disease severities. The mortality rate due to COVID-19 during hospitalization was 3.6% (1/28) in the immunocompromised group, with no difference between the two groups. Three cases of re-exacerbation after discharge occurred in the immunocompromised group and none in the control group. Linear regression based on nasopharyngeal real-time-PCR cycle threshold (Ct) values according to the time since symptom onset showed markedly slower viral clearance in the immunocompromised group than in the control group (P Immunocompromised individuals receiving immunosuppressive medications are more likely to show delayed post-infection SARS-CoV-2 viral clearance and the development of viremia, potentially resulting in worsening severity and outcomes, especially in viremic patients, even during the Omicron epidemic.
Sections du résumé
BACKGROUND
BACKGROUND
The prognosis of immunocompromised individuals with COVID-19 remains a significant concern. Information regarding the clinical and virological characteristics of immunocompromised patients infected with SARS-CoV-2 during the Omicron variant period is limited.
METHODS
METHODS
Medical records of patients admitted to our hospital with COVID-19 during the Omicron (BA.1-5) epidemic were retrospectively reviewed. Clinical, virological (nasopharyngeal swabs and blood), and serological data were compared between immunocompromised patients receiving immunosuppressive medications (calcineurin inhibitors, mycophenolate mofetil, or steroids) and control patients not receiving immunosuppressive medications.
RESULTS
RESULTS
Twenty-eight immunocompromised patients (25 transplant recipients) and 26 control patients were included. Fourteen of the immunocompromised patients (50%) received monoclonal antibodies. The immunocompromised group included 15 mild/moderate (53.6%), 10 severe (35.7%), and three critical (10.7%) disease severities. The mortality rate due to COVID-19 during hospitalization was 3.6% (1/28) in the immunocompromised group, with no difference between the two groups. Three cases of re-exacerbation after discharge occurred in the immunocompromised group and none in the control group. Linear regression based on nasopharyngeal real-time-PCR cycle threshold (Ct) values according to the time since symptom onset showed markedly slower viral clearance in the immunocompromised group than in the control group (P
CONCLUSIONS
CONCLUSIONS
Immunocompromised individuals receiving immunosuppressive medications are more likely to show delayed post-infection SARS-CoV-2 viral clearance and the development of viremia, potentially resulting in worsening severity and outcomes, especially in viremic patients, even during the Omicron epidemic.
Identifiants
pubmed: 39060971
doi: 10.1186/s12879-024-09633-1
pii: 10.1186/s12879-024-09633-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
736Informations de copyright
© 2024. The Author(s).
Références
Hoek RAS, Manintveld OC, Betjes MGH, Hellemons ME, Seghers L, Van Kampen JAA, Caliskan K, van de Wetering J, van den Hoogen M, Metselaar HJ, et al. COVID-19 in solid organ transplant recipients: a single-center experience. Transpl Int. 2020;33(9):1099–105.
doi: 10.1111/tri.13662
pubmed: 32460390
Heldman MR, Kates OS, Safa K, Kotton CN, Georgia SJ, Steinbrink JM, Alexander BD, Hemmersbach-Miller M, Blumberg EA, Multani A, et al. Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic. Am J Transplant. 2022;22(1):279–88.
doi: 10.1111/ajt.16840
pubmed: 34514710
pmcid: 8653312
Kalil AC, Florescu DF. Mortality in solid organ transplant recipients hospitalized for COVID-19. Am J Transplant. 2022;22(1):12–3.
doi: 10.1111/ajt.16885
pubmed: 34738312
pmcid: 8652626
Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, Barbian K, Judson SD, Fischer ER, Martens C, et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell. 2020;183(7):1901-1912.e1909.
doi: 10.1016/j.cell.2020.10.049
pubmed: 33248470
pmcid: 7640888
Aydillo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A, Dutta J, van Bakel H, Aberg J, García-Sastre A, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med. 2020;383(26):2586–8.
doi: 10.1056/NEJMc2031670
pubmed: 33259154
Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, Hinsley W, Bernal JL, Kall M, Bhatt S, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and (B.1.617.2) delta variants in England: a cohort study. Lancet. 2022;399(10332):1303–12.
doi: 10.1016/S0140-6736(22)00462-7
pubmed: 35305296
pmcid: 8926413
Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, Louca P, May A, Figueiredo JC, Hu C, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399(10335):1618–24.
doi: 10.1016/S0140-6736(22)00327-0
pubmed: 35397851
pmcid: 8989396
Christensen PA, Olsen RJ, Long SW, Snehal R, Davis JJ, Ojeda Saavedra M, Reppond K, Shyer MN, Cambric J, Gadd R, et al. Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston. Texas Am J Pathol. 2022;192(4):642–52.
doi: 10.1016/j.ajpath.2022.01.007
pubmed: 35123975
Blennow O, Salmanton-García J, Nowak P, Itri F, Van Doesum J, López-García A, Farina F, Jaksic O, Pinczés LI, Bilgin YM, et al. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report. Am J Hematol. 2022;97(8):E312–7.
doi: 10.1002/ajh.26626
pubmed: 35702878
pmcid: 9349555
Lafont E, Pere H, Lebeaux D, Cheminet G, Thervet E, Guillemain R, Flahault A. Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19. J Antimicrob Chemother. 2022;77(10):2688–92.
doi: 10.1093/jac/dkac253
pubmed: 35876174
Malahe SRK, Hoek RAS, Dalm VASH, Broers AEC, den Hoed CM, Manintveld OC, Baan CC, van Deuzen CM, Papageorgiou G, Bax HI, et al. Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective. Observational Study Clin Infect Dis. 2023;76(3):e172–8.
doi: 10.1093/cid/ciac571
pubmed: 35869843
National Institute of Health. COVID-19 Treatment Guidelines. Special Considerations in People Who Are Immunocompromised. https://www.covid19treatmentguidelines.nih.gov/special-populations/immunocompromised/ . Accessed 12 Mar 2024.
Nakakubo S, Kishida N, Okuda K, Kamada K, Iwama M, Suzuki M, Yokota I, Ito YM, Nasuhara Y, Boucher RC, et al. Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study. Lancet Infect Dis. 2023;23(11):1244–56.
doi: 10.1016/S1473-3099(23)00271-2
pubmed: 37399831
National Institute of Health. COVID-19 Treatment Guidelines. Clinical Spectrum of SARS-CoV-2 Infection. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/ . Accessed 12 Mar 2024.
Takahashi K, Ishikane M, Ujiie M, Iwamoto N, Okumura N, Sato T, Nagashima M, Moriya A, Suzuki M, Hojo M, et al. Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees. Emerg Infect Dis. 2022;28(5):998–1001.
doi: 10.3201/eid2805.220197
pubmed: 35290176
pmcid: 9045443
Dimcheff DE, Blair CN, Zhu Y, Chappell JD, Gaglani M, McNeal T, Ghamande S, Steingrub JS, Shapiro NI, Duggal A, et al. Total and Subgenomic RNA Viral Load in Patients Infected With SARS-CoV-2 Alpha, Delta, and Omicron Variants. J Infect Dis. 2023;228(3):235–44.
doi: 10.1093/infdis/jiad061
pubmed: 36883903
pmcid: 10420395
Wong CKH, Lau KTK, Au ICH, Lau EHY, Poon LLM, Hung IFN, Cowling BJ, Leung GM. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study. Lancet Infect Dis. 2023;23(6):683–95.
doi: 10.1016/S1473-3099(22)00873-8
pubmed: 36796397
pmcid: 9949892
Lu X, Wang L, Sakthivel SK, Whitaker B, Murray J, Kamili S, Lynch B, Malapati L, Burke SA, Harcourt J, et al. US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020;26(8):1654–65.
doi: 10.3201/eid2608.201246
pubmed: 32396505
pmcid: 7392423
Wong CKH, Lau KTK, Au ICH, Lau EHY, Poon LLM, Hung IFN, Cowling BJ, Leung GM. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study. Lancet Infect Dis. 2023;23(6):683–95.
doi: 10.1016/S1473-3099(22)00873-8
pubmed: 36796397
pmcid: 9949892
Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R: COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. medRxiv [Preprint]. 2022.
Saá P, Fink RV, Dawar H, Di Germanio C, Montalvo L, Wright DJ, Krysztof DE, Kleinman SH, Nester T, Kessler DA, et al. Prevalence of SARS-CoV-2 Viremia in Presymptomatic Blood Donors in the Delta and Omicron Variant Eras. Open Forum Infect Dis. 2023;10(5):ofad253.
doi: 10.1093/ofid/ofad253
pubmed: 37250174
pmcid: 10220507
Li Y, Schneider AM, Mehta A, Sade-Feldman M, Kays KR, Gentili M, Charland NC, Gonye AL, Gushterova I, Khanna HK, et al. SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes. J Clin Invest. 2021;131(13):e148635.
doi: 10.1172/JCI148635
pubmed: 34196300
pmcid: 8245177
Hagman K, Hedenstierna M, Gille-Johnson P, Hammas B, Grabbe M, Dillner J, Ursing J. Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Serum as Predictor of Severe Outcome in Coronavirus Disease 2019: A Retrospective Cohort Study. Clin Infect Dis. 2021;73(9):e2995–3001.
doi: 10.1093/cid/ciaa1285
pubmed: 32856036
Ram-Mohan N, Kim D, Zudock EJ, Hashemi MM, Tjandra KC, Rogers AJ, Blish CA, Nadeau KC, Newberry JA, Quinn JV, et al. SARS-CoV-2 RNAemia Predicts Clinical Deterioration and Extrapulmonary Complications from COVID-19. Clin Infect Dis. 2022;74(2):218–26.
doi: 10.1093/cid/ciab394
pubmed: 33949665
Bermejo-Martin JF, García-Mateo N, Motos A, Resino S, Tamayo L, Ryan Murua P, Bustamante-Munguira E, Gallego Curto E, Úbeda-Iglesias A, de la Torre MDC, et al. Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: a multicentre, prospective, cohort study. Lancet Microbe. 2023;4(6):e431–41.
doi: 10.1016/S2666-5247(23)00041-1
pubmed: 37116517
pmcid: 10129133
Centers for Disease Control and Prevention. Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic. https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html . Accessed 31 Mar 2024.